• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      Aim for deep response (uMRD) as part of your patients' treatment goals

      Science of deep response

      Achieving deep response early can help improve survival outcomes for patients with CLL1-3

      Deep response, or undetectable minimal residual disease (uMRD), is defined as <1 tumour cell per 104 white cells. It is a powerful prognostic tool that demonstrates an inverse relationship with patient outcomes.1

      How low can you go?

      Select a patient to see how choosing a treatment capable of achieving deep response could improve their outcomes1

      Hypothetical scenarios of CLL burden during and after therapy.
      Adapted from Bottcher et al, 2013.1
      CLL = chronic lymphocytic leukaemia; MRD = minimal residual disease.

       

      Survival benefits

      References

      1. Böttcher S, et al. Hematol Oncol Clin North Am. 2013;27(2):267-288.
      2. Kwok M, et al. Blood 2016;128: 2770–2773.
      3. Langerak AW, et al. Blood 2019;133(Suppl.): 494–497.

       

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      UK-VNCCLL-200348. Date of preparation: October 2020.